Unicycive Therapeutics (UNCY) Expected to Announce Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) is expected to be issuing its quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Unicycive Therapeutics Trading Down 11.6 %

UNCY stock opened at $0.55 on Friday. The company’s 50 day moving average is $0.59 and its 200 day moving average is $0.61. The stock has a market cap of $65.86 million, a price-to-earnings ratio of -0.57 and a beta of 2.14. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.16.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Guggenheim began coverage on Unicycive Therapeutics in a report on Monday, April 21st. They issued a “buy” rating and a $6.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $7.50 price objective on shares of Unicycive Therapeutics in a research report on Friday, April 11th.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.